“An Unrelenting Disaster Zone”: Merck’s Alzheimer’s Drug Fails in Phase III Post author:Sam Post published:February 13, 2018 Post category:BioPharma Alzheimer’s drug development took another hit. Source: BioSpace You Might Also Like <b>Vicarius Pharma</b> Launches With $21.8 Million and Will be Helmed by Former Biogen-Elan Exec August 13, 2017 Portola Plunges After Hint of Delay for FDA Approval of Factor Xa-inhibitor February 28, 2018 <b>Martin Shkreli's</b> Complaint Leads to a $100 Million FTC Settlement for This Biotech January 18, 2017
<b>Vicarius Pharma</b> Launches With $21.8 Million and Will be Helmed by Former Biogen-Elan Exec August 13, 2017
<b>Martin Shkreli's</b> Complaint Leads to a $100 Million FTC Settlement for This Biotech January 18, 2017
